ENTERO HEALTHCARE SOLU L
Latest filings
Next results: Wed, 4 Nov · Financial Results/Other business matters- Board to review September quarter results on November 4 · Results
- Routine quarterly RTA certificate under SEBI Depositories Regulations · Compliance
- Allotment of 43,155 equity shares under ESOP 2023 to eligible employees · Capital Market Events
Snapshot
What the business is, and whether it's a good one at a fair price.
Distributes pharmaceutical and healthcare products to a retail network of more than 105,300 pharmacies and 3,600 hospitals, supported by 136 warehouses, 137 offices and 48 subsidiaries spread across 21 states and 523 districts. In FY26, the business reported revenue of Rs 6,591 crore, up 29.3% year-on-year with 31.5% like-for-like growth, while EBITDA rose 55% to Rs 266 crore at a 4.0% margin. Growth has come from a mix of like-for-like expansion and acquisitions — seven acquisitions were completed during the year, including a 51.51% stake in Anand Chemiceutics. A MedTech line has scaled to annualized revenue exceeding Rs 1,000 crore, and the company employs about 4,970 staff. Stated operating cost items are employee costs at 3.7% of revenue, other operating expenses at 2.6% and depreciation at 0.7%, with capex at 1.0% of revenue. Operating cash flow turned positive at Rs 96 crore in FY26, although Q4 FY26 absorbed Rs 114 million in one-off items including business contract closure expenses and write-offs.
Scorecard
Measured from the filed financials, judged against its Retailing peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from ENTERO HEALTHCARE SOLU L's filed financials and exchange disclosures
What does ENTERO HEALTHCARE SOLU L do?
ENTERO HEALTHCARE SOLU L is a Retailing company listed on NSE and BSE, trading under the symbol ENTERO.
Is ENTERO HEALTHCARE SOLU L profitable?
Yes. Over the trailing twelve months ENTERO HEALTHCARE SOLU L reported a net profit of ₹168 Cr on revenue of ₹7,128 Cr.
Does ENTERO HEALTHCARE SOLU L pay a dividend?
Not in the latest reported year — ENTERO HEALTHCARE SOLU L's dividend payout for FY26 was nil.
Is ENTERO HEALTHCARE SOLU L debt-free?
No. It reported borrowings of ₹567 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹420 Cr after cash. Debt stands at 0.32× equity. That is higher than 77% of its 49 Retailing peers.
Is ENTERO HEALTHCARE SOLU L expensive compared with its peers?
On trailing P/E, ENTERO HEALTHCARE SOLU L ranks 43 of 52 in Retailing — cheaper than 18% of them, against an industry median of 23.2×. This is a position, not a valuation judgement.
How much does the ENTERO HEALTHCARE SOLU L share price move in a day?
On a typical session ENTERO HEALTHCARE SOLU L moves 1.34% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
When are ENTERO HEALTHCARE SOLU L's next results?
Financial Results/Other business matters on Wed, 4 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track ENTERO HEALTHCARE SOLU L's announcements?
Every NSE and BSE filing by ENTERO HEALTHCARE SOLU L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.